Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of INX-08189 with Victrelis in Healthy Subjects
NCT01471717Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-986094 in hepatitis C (HCV) (4 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Pharmacokinetic parameters of INX-08189, INX-08032, and Victrelis and Safety parameters at Day 14. Started Oct 2011; status: completed.
02
Drugs
BMS-986094
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01471717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01471717.